Alembic Limited
Alembic Limited's Board recommended a final dividend of Rs.2.4 per equity share for FY2025-26. The record date for the dividend is August 4, 2026, and the payment is expected by September 10, 2026, post AGM approval on August 11, 2026.
May 19 2026 18:14:56
Alembic Ltd - 506235 - Board Meeting Outcome for Outcome Of The Board Meeting
Alembic's board approved Q4 FY26 consolidated net profit of ₹9.61 crore, marking a 59.5% YoY decline. For the full year FY26, consolidated net profit decreased by 12.9% to ₹125.93 crore, despite an 8.2% increase in total revenue to ₹239.99 crore. The company also recommended a final dividend of ₹2.40 per equity share for FY26.
May 19 2026 17:55:13
Alembic Pharma Q4 profit up 29% as US formulations business grows 11%; declares ₹12 dividend
Alembic Pharma reported a 29% year-on-year increase in its Q4 net profit, driven by an 11% growth in its US formulations business. The company also declared a final dividend of ₹12 per equity share for the financial year ended March 31, 2026.
May 15 2026 15:53:10
Alembic Pharma shares rise on USFDA nod for prostate cancer drug with $3 billion estimated market size
Alembic Pharmaceuticals has received USFDA tentative approval for its Darolutamide Tablets, 300 mg, a prostate cancer medication that is therapeutically equivalent to Bayer's Nubeqa. This approval targets an estimated US$3.155 billion market for the twelve-month period ending March 2026, contingent upon the expiry of patent protections or exclusivity periods.
May 14 2026 11:24:11
Alembic Ltd - 506235 - Board Meeting Intimation for Considering Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2026
Alembic Limited's Board of Directors will hold a meeting on May 19, 2026. The agenda includes considering and approving the audited financial results for the quarter and financial year ended March 31, 2026, and recommending a dividend on Equity Shares.
May 08 2026 12:52:54
Read More